Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC) Clinical Trial

Official title:

A Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study to Compare Toripalimab Combined With Lenvatinib Versus Placebo Combined With Lenvatinib as the 1st-line Therapy for Advanced HCC

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04523493
• Other study ID #: JS001-027-III-HCC
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: June 29, 2020
• Est. completion date: September 1, 2026

Study information

• Verified date: July 2023
• Source: Shanghai Junshi Bioscience Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced HCC.

Eligible subjects will be randomized at a ratio of 2:1 to receive Toripalimab combined with Lenvatinib (experimental group) or Placebo combined with Lenvatinib (control group).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 530
• Est. completion date: September 1, 2026
• Est. primary completion date: May 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria:

1. Age of 18-75 full years (inclusive), male or female.

2. Histopathologically or cytologically confirmed HCC or participants with liver cirrhosis meet the clinical diagnostic criteria for HCC of the American Association for the Study of Liver Diseases (AASLD).

3. Stage B (intermediate stage) or C (advanced stage) HCC determined in accordance with Barcelona Clinic Liver Cancer staging system (BCLC stage), be unsuitable for surgery and/or local therapy, or have progression of disease after surgery and/or local therapy.

4. No previous use of any systemic therapy for HCC (mainly including systemic chemotherapy, antiangiogenic drugs or other molecular targeted therapy, immunotherapy containing CTLA-4, PD 1/PD-L1 monoclonal antibody).

5. Having = 1 measurable lesion in accordance with RECIST v1.1. Requirement: the selected target lesion has not been treated locally before, or is located in the area of previous local therapy and subsequently determined as PD through radiological examination and in accordance with RECIST v1.1.

6. Child-Pugh class A or =7 class B, with no history of hepatic encephalopathy.

7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score 0-1.

8. Expected survival =12 weeks.

9. Main organ function meets the following requirements: no blood transfusion within 14 days prior to screening, no use of hematopoietic stimulating factor (including G-CSF, GM-CSF, EPO and TPO etc.) or human albumin preparation.

10. In case of HBsAg (+) and/or HBcAb (+), HBV DNA is required to be < 1000 IU/mL (if the lowest detectable value at the local center is higher than 1000IU/mL, enrollment can be determined based on the specific condition after discussed with sponsor), and it is required to continue original anti-HBV therapy in the full course, or start to use Entecavir or tenofovir in the full course after screening during the study.

11. Female patients at childbearing age must receive serum pregnancy test within 7 days before randomization, have negative result, and are willing to use reliable and effective contraceptive methods during the trial and within 60 days after last administration. Male patients whose partners are women of childbearing potential must agree to use reliable and effective contraceptive methods during the trial and within 60 days after last administration.

12. Being voluntary to participate in the study, sufficiently informed consent and sign the written informed consent form, with good compliance.

Exclusion criteria:

1. Known cholangiocellular carcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma and hepatic fibrolamellar carcinoma.

2. Malignant tumor except HCC within 5 years: however, localized tumor cured in the study is excluded,including cervical carcinoma in situ, skin basal cell carcinoma and carcinoma in situ of prostate.

3. Hepatic surgery and/or local therapy or treatment with investigational product for HCC within 4 weeks prior to randomization; palliative radiation therapy for bone metastatic lesion within 2 weeks prior to randomization; use of Chinese medicine preparations with anti-liver cancer effect within two weeks prior to randomization. Toxicity induced by previous therapy (except alopecia) not recovered to = grade 1 (NCI-CTCAE v5.0).

4. Prior use of other anti-PD-1 antibody or other immunotherapy targeting PD-1/PD-L1.

5. Uncontrolled pericardial effusion, uncontrolled pleural effusion or clinically obvious moderate or severe peritoneal effusion at screening, defined as reaching the following criteria: having clinical symptoms and pleural and peritoneal effusion detected in physical examination at screening; or puncture for drainage required for pleural and peritoneal effusion and/or intracavitary administration during screening.

6. History of gastrointestinal hemorrhage within 6 months prior to randomization or clear tendency of gastrointestinal hemorrhage (including severe esophageal-gastric varices with hemorrhagic risk, locally active peptic ulcer, persistent fecal occult blood (+)).

7. Having = grade 3 (NCI-CTCAE v5.0) gastrointestinal or non-gastrointestinal fistula at present.

8. Cancer thrombus invasion in the main trunk of portal vein (Vp4) (more than 1/2 of the lumen), inferior vena cava cancer thrombus or cardiac involvement in accordance with CT/MRI.

9. Serious cardiovascular and cerebrovascular diseases:

10. Other obvious hemorrhagic tendency or evidence on important coagulation disorder:

11. Medium to large surgical treatment within 4 weeks prior to randomization, not including diagnostic biopsy.

12. Know central nervous system metastasis; cranial and/or spinal MRI is needed for exclusion if central nervous system metastasis is suspected.

13. Serious, uncured wound, active ulcer or untreated bone fracture.

14. Vaccination of live vaccine within 30 days prior to randomization.

15. Presence of immunodeficiency or receiving long-term systemic steroid therapy within 7 days prior to randomization (daily dose >10mg Prednisone or other equivalent glucocorticoid), or other immunosuppressive therapy.

16. Active autoimmune diseases requiring systemic treatment (i.e., immunomodulatory drug, corticosteroid or immunosuppressant) in the past two years; however, replacement therapy (e.g., thyroxine, insulin or physiological corticosteroid replacement therapy for renal or pituitary insufficiency) will not be considered as systemic therapy and is allowed to be used.

17. History of clear interstitial lung disease or non-infectious pneumonia, unless induced by local radiotherapy.

18. Active tuberculosis or received antituberculosis therapy within 1 year prior to randomization.

19. Any serious acute and chronic infection requiring systemic antibacterial, antifungal or antiviral therapy at screening, not including viral hepatitis.

20. Known history of human immunodeficiency virus (HIV) infection.

21. Previously receiving allogeneic stem cell or solid organ transplantation.

22. Inability to swallow tablets, malabsorption syndrome or any other condition that affects gastrointestinal absorption.

23. Known history of serious allergy to any monoclonal antibody, anti-angiogenesis drug.

24. Other participants who are unsuitable for inclusion as judged by the investigator."

Related Conditions & MeSH terms

• Advanced Hepatocellular Carcinoma (HCC)
• Carcinoma, Hepatocellular

Intervention

Combination Product:
• Toripalimab combined with Lenvatinib
Experimental group: Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 12 mg/day (Body Weight=60 kg) or 8 mg/day (Body Weight<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.
• Placebo combined with Lenvatinib
Control group: Placebo, one unit, IV infusion, once every 3 weeks, combined with Lenvatinib 12 mg/day (Body Weight=60 kg) or 8 mg/day (Body Weight<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.

Locations

Country	Name	City	State
China	Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command	Nanjing	Jiangsu
Italy	Azienda Ospedaliera Universitaria Careggi	Firenze
Italy	Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico,Oncologia Medica	Milan
Italy	IRCCS Fondazione Giovanni Pascale, Istituto Nazionale Dei Tumori	Napoli
Italy	Azienda Ospedaliero Universitaria Pisana	Pisa
Italy	A.O.U. Citta della Salute e della Scienza di Torino	Tortona
Italy	AOUI Verona - Policlinico "G.B. Rossi" di Borgo Roma	Verona
Poland	Copernicus Podmiot Leczniczy sp. z o.o., Wojewodzkie Centrum Onkologii, Oddzial Onkologii Klinicznej/Chemioterapii	Gdansk
Poland	Szpital Wojewódzki im. Mikolaja Kopernika w Koszalinie, Oddzial Dzienny Chemioterapii	Koszalin
Poland	PRATIA MCM Kraków, ul. Pana Tadeusza 2,	Krakow
Poland	ID Clinic	Myslowice
Poland	Wielkopolskie Centrum Onkologii, Oddzial Onkologii Klinicznej i Immunoonkologii z Pododdzialem Dziennym i Izba Przyjec	Poznan
Poland	Centrum Medyczne Pratia Poznan	Skórzewo
Poland	Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Onkologii i Radioterapii	Warszawa
Singapore	National Cancer Centre Singapore	Singapore
Ukraine	Communal Non-commercial Enterprise City Clinical Hospital #4 of Dnipro City Council, Department of Chemotherapy	Dnipro
Ukraine	Communal Non-profit Enterprise "Regional Center of Oncology", Department of Abdominal Organs Oncosurgery	Kharkiv
Ukraine	Communal Non-Profit Institution of Kharkiv Regional Council Regional Clinical Specialized Dispensary of Radiation Protection of Population	Kharkiv
Ukraine	State Inst.O.O.Shalimov Nat.Institute of Surgery and Transplantology of Nat.Academy of Med.Sciences of Ukraine, Dep.of Oncology	Kyiv
Ukraine	Communal Enterprise Volyn Regional Clinical Hospital of Volyn Regional Council	Luts'k
Ukraine	Communal Non-commercial Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council, Department of General Surgery	Odesa
Ukraine	Communal Non-commercial Enterprise of Sumy Regional Council, Sumy Regional Clinical Oncological Dispensar	Sumy
Ukraine	Communal Non-commercial Enterprise Zaporizhzhia Regional Antitumor Center of Zaporizhzhia Regional Council	Zaporizhzhia
United States	Alliance for Multispecialty Research, LLC	Kansas City	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Junshi Bioscience Co., Ltd.

Countries where clinical trial is conducted

United States,  China,  Italy,  Poland,  Singapore,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assessment of the correlation between tumor cell PD-L1 expression level/ percentage and efficacy	Tumor biopsy specimen collected before the treatment and tumor specimen collected at progression of tumor will be used for immunohistochemical staining test to determine the expression of PD-L1	Up to 3 years
Other	Tumor mutation burden (TMB)	Correlation between TMB of tumor tissue and the efficacy	Up to 3 years
Primary	Overall survival (OS)	The time from randomization to death for any reason.	Up to 3 years
Secondary	ORR	Defined as the proportion of subjects with the best overall response of complete response (CR) or partial response (PR).	Up to 3 years
Secondary	Duration of Response (DOR)	Defined as the time from the first evaluation of CR or PR to the first evaluation of PD or death for any reason.	Up to 3 years
Secondary	DCR	Defined as the proportion of subjects with the best overall response (BOR) of CR, PR or SD.	Up to 3 years
Secondary	TTP	Defined as the time from randomization to objective tumor progression.	Up to 3 years
Secondary	Progression-free survival (PFS)	The time from randomization to progression of disease or death for any reason, whichever comes first. Progression of disease will be evaluated	Up to 3 years
Secondary	PFS rate	The PFS rate on 6 months and 1year in both groups.	Up to 3 years
Secondary	OS rate	The OS rate on 1year and 2years in both groups.	Up to 3 years
Secondary	Incidence,severity and prognosis of AEs/SAEs as assessed by NCI-CTCAE v5.0	Verbatim descriptions of adverse events will correspond to MedDRA synonymous terms, and AEs will be graded in accordance with NCI-CTCAE version 5.0. All the adverse events during or after the first dose of study drug will be summarized by treatment groups and NCI CTCAE grade. In addition, serious adverse events, adverse events (grade 3 or above) and the adverse events leading to discontinuation or suspension of study drug will be summarized correspondingly. Multiple occurrence of the same event will be counted once in accordance with the highest severity. The proportion of subjects with at least one adverse event will be reported by term of toxicity and treatment groups.	From date of consent informed until 90 days after the last investigational product administration. Up to 2 approximately years.
Secondary	PK	According to the test of blood samples, the pharmacokinetic parameters of Toripalimab, mainly trough concentration, will be analyzed.	To be collected once within 60 minutes prior to administration each for Toripalimab/placebo on Day 1 of Cycle (each cycle is 21 days). but the no-china sites not collection the sample
Secondary	Immunogenicity	Plasma level of anti-Toripalimab injection (JS001) antibody, immunoglobulin and Toripalimab injection (JS001) will be summarized descriptively.	Up to 3 years